BTR-1 |
| Catalog No.GC34511 |
BTR-1 est un agent anticancéreux actif, provoque l'arrêt de la phase S et affecte la réplication de l'ADN dans les cellules leucémiques. BTR-1 active l'apoptose et induit la mort cellulaire.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 18331-34-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BTR-1 is an active anti-cancer agent, causes S phase arrest, and affects DNA replication in leukemic cells. BTR-1 activates apoptosis and induces cell death[1]. Apoptosis[1]
BTR-1 (10, 50, 100, and 250 µM, 5 days) dose-dependently causes cytotoxicity in human leukemic cells, with IC50s of 8 and 6 µM at 48 and 72 h, respectively[1]. Cell Viability Assay[1] Cell Line: T-cell leukemic cell lines
[1]. Moorthy BT, et al. Novel rhodanine derivatives induce growth inhibition followed by apoptosis. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6297-301.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *